ClinicalTrials.Veeva

Menu
A

Adams Clinical Watertown

Research site

Site insights

Top conditions

Top treatments

Rapastinel
SPD489
Dasotraline
LY3002813
Donanemab
LSD D-Tartrate
MM120
Seltorexant
serotonin
Vilazodone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Contact this site

Kenny Shuster

Verified by this site

Active trials

17 of 62 total trials

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (TRONTIER 2)

The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild c...

Enrolling
Alzheimers Disease
Drug: Trontinemab
Other: Placebo

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized A...

Enrolling
Generalized Anxiety Disorder
Drug: MM120 (LSD D-Tartrate)
Other: Placebo

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depress...

Enrolling
Major Depressive Disorder
Other: Placebo
Drug: MM120 (LSD D-Tartrate)

X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of...

Enrolling
Major Depressive Disorder
Drug: Azetukalner
Drug: Placebo

The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC), compared with placebo pl...

Enrolling
Bipolar Disorder
Drug: Brenipatide
Drug: Placebo

This study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptom...

Active, not recruiting
Alzheimer's Disease
Mental Disorders
Drug: Dexamethasone
Drug: Placebo

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The purpose of this study is to measure the difference in time to developing or worsening memory, thinking, or functional problems due to Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Drug: Placebo
Drug: Remternetug

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early symptomatic A...

Active, not recruiting
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

This Phase 2 study (protocol number VLS-01-203) will determine the efficacy, safety, and tolerability of short-term treatment with a VLS-01 transmuco...

Enrolling
Treatment Resistant Depression
Drug: VLS-01-BU Placebo
Drug: VLS-01-203 BU

The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD).For any individual participant, th...

Enrolling
Alcohol Use Disorder
Drug: Mazdutide
Drug: Placebo

The purpose of the study is to evaluate the long term safety and tolerability of troriluzole as adjunctive therapy in subjects with obsessive compuls...

Invitation-only
Obsessive Compulsive Disorder
Drug: Troriluzole (BHV-4157)

The purpose of this study is to evaluate the long-term safety and tolerability of BHV-7000, in participants with Major Depressive Disorder (MDD).

Invitation-only
Major Depressive Disorder
Drug: BHV-7000

Primary: To evaluate the efficacy of CTN in adults ages with ADHD and comorbid anxiety (AISRS) Key Secondary: To assess the efficacy of CTN in adults...

Enrolling
Social Anxiety Disorder
Anxiety
Other: Placebo
Drug: Centanafadine

The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with plac...

Enrolling
Depressive Disorder, Major
Drug: Selective Serotonin Reuptake Inhibitor (SSRI)/Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Drug: Placebo

This is a long- term extension of the double-blind trials APPROACH (CYB003-002) and EMBRACE (CYB003-003). Its aim is to examine the safety and long-t...

Enrolling
Major Depressive Disorder
Drug: CYB003
Locations recently updated

This study is a pre-screening process used to assess participants' potential eligibility for Roche interventional Alzheimer's disease studies.

Enrolling
Alzheimers Disease
Other: No Intervention

Trial sponsors

Lilly logo
Allergan logo
Indivior logo
Shire logo
A
Janssen (J&J Innovative Medicine) logo
Otsuka logo
Forest Laboratories logo
M
Sumitomo Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems